Michael Hayden

PhD, FRSC, FRCPC, MBChB, OBC

Investigator, BC Children's Hospital
Canada Research Chair in Human Genetics and Molecular Medicine
University Killam Professor, Department of Medical Genetics, University of British Columbia

Dr. Hayden’s work focuses on understanding the genetic roots of illness and using that understanding to develop better approaches to treatment for children and families. Author of approximately 950 peer-reviewed publications, Dr. Hayden’s research is primarily on translational medicine, including Huntington Disease, predictive, personalized medicine, drug development, and gene therapy. His research group identified the first mutations underlying Lipoprotein Lipase (LPL) Deficiency in childhood and developed gene therapy approaches to treat this condition resulting in the first approved gene therapy product (Glybera) in a major market. Dr. Hayden is the most cited author in the world on ABCA1 and Huntington Disease.